Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAdvanced Medical Solutions Group Regulatory News (AMS)

Share Price Information for Advanced Medical Solutions Group (AMS)

Share Price is delayed by 15 minutes
Get Live Data
218.00    -3.00 (-1.36%)
Bid:
217.50
Ask:
218.50
Spread: 1.00 (0.46%)
Market Cap: £473.56m
AMS Live PriceLast checked at - London Stock Exchange

Intraday Advanced Medical Solutions Group Share Chart

AGM Statement

20 May 2014 07:00

RNS Number : 5053H
Advanced Medical Solutions Grp PLC
20 May 2014
 



 

20 May 2014

 

Advanced Medical Solutions Group plc

("AMS")

 

Annual General Meeting

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, will hold its Annual General Meeting ("AGM") at 11.00 today at the offices of Tavistock Communications, 131 Finsbury Pavement, London, EC2A 1NT.

 

Chris Meredith, AMS's Chief Executive Officer, will give a presentation at the AGM, the slides from which will be made available on the Company's website www.admedsol.com. No new material information will be provided.

 

In line with last year's practice, AMS will be providing an update on trading in late June.

 

- ends -

 

For further information, please contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director

 

 

 

Tavistock Communications

Tel: +44 (0) 20 7920 3150

John West / Chris Munden / Andrew Dunn

 

 

 

Investec Bank plc

Tel: +44 (0) 20 7597 5970

Daniel Adams

 

 

About Advanced Medical Solutions Group plc - see www.admedsol.com 

 

Founded in 1991, AMS is a leader in the development and manufacture of innovative and technologically advanced products for the US$15 billion global wound care market. Through a mix of organic development and a number of acquisitions, AMS now has a wide range of products based on technologies that include alginates, silver alginates, foams, collagens, cyanoacrylate adhesives and sutures.

 

AMS manufactures wound care products for an extensive list of Original Equipment Manufacturer ("OEM") customers around the world, but the majority of the Group's revenues now come from its own brands - ActivHeal® wound care products in the UK to the NHS, LiquiBand® cyanoacrylate products primarily in the UK, Europe and the USA, and RESORBA® sutures and collagen wound care products primarily in Europe. AMS develops innovative products from its R&D pipeline which it commercialises globally, either directly or through partnerships with its OEM customers.

 

AMS's products are sold globally via a network of regional or multinational partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia.

 

With 450 employees operating under four distinct business units (Branded Direct, Branded Distributed, OEM and Bulk Materials) that match its multiple products and routes-to-market, AMS's products are manufactured from two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMSFAFIUFLSESI
Date   Source Headline
18th Oct 20244:16 pmRNSHolding(s) in Company
11th Oct 20247:00 amRNSDirector/PDMR Shareholding
30th Sep 20245:02 pmRNSTotal Voting Rights
18th Sep 20247:00 amRNSInterim Results
30th Aug 20244:53 pmRNSTotal Voting Rights
29th Aug 20247:00 amRNSNotice of Interim Results
31st Jul 20242:54 pmRNSTotal Voting Rights
15th Jul 20247:00 amRNSHalf Year Trading update
4th Jul 20247:00 amRNSClosing of Peters Surgical acquisition
1st Jul 202410:40 amRNSTotal Voting Rights
27th Jun 20247:00 amRNSRegulatory Approval for acquisition
12th Jun 20241:47 pmRNSResults of Annual General Meeting
12th Jun 20247:00 amRNSAnnual General Meeting
5th Jun 20248:42 amRNSHolding(s) in Company
3rd Jun 20245:27 pmRNSTotal Voting Rights
13th May 20245:53 pmRNSAnnual Report and Notice of Annual General Meeting
1st May 20249:10 amRNSTotal Voting Rights
26th Apr 20249:17 amRNSDirector/PDMR Shareholding
25th Apr 20243:41 pmRNSHolding(s) in Company
17th Apr 20243:30 pmRNSHolding(s) in Company
4th Apr 20243:17 pmRNSHolding(s) in Company
2nd Apr 20242:47 pmRNSDirector/PDMR and PCA Shareholding
28th Mar 20245:04 pmRNSTotal Voting Rights
18th Mar 202412:35 pmRNSDirector/PDMR Shareholding
13th Mar 20247:03 amRNSProposed acquisition of Peters Surgical
13th Mar 20247:03 amRNSUnaudited Preliminary Results
12th Mar 20247:00 amRNSBlock listing Interim Review
10th Jan 20247:00 amRNSFull Year Trading Update
30th Nov 20235:11 pmRNSTotal Voting Rights
31st Oct 20235:02 pmRNSTotal Voting Rights
25th Oct 20237:00 amRNSUS LiquiBand® distribution agreements signed
2nd Oct 20237:01 amRNSDirector/PDMR Shareholding
2nd Oct 20237:00 amRNSAppointment of New Chair
27th Sep 20235:55 pmRNSDirector/PDMR Shareholding
25th Sep 20233:15 pmRNSHolding(s) in Company
20th Sep 20237:00 amRNSInterim Results
18th Sep 20237:00 amRNSLiquiBand Fix8® US commercialisation agreement
14th Sep 20233:52 pmRNSBlock listing Interim Review
4th Sep 20237:00 amRNSTrading Statement
31st Aug 20235:56 pmRNSTotal Voting Rights
10th Aug 20237:00 amRNSNotice of Interim Results
31st Jul 20234:51 pmRNSTotal Voting Rights
11th Jul 20237:00 amRNSHalf Year Trading Update
30th Jun 20232:14 pmRNSTotal Voting Rights
19th Jun 202312:18 pmRNSStandard form for notification of major holdings
5th Jun 20237:00 amRNSUS regulatory approval granted for LiquiBandFix8®
31st May 20232:08 pmRNSResults of Annual General Meeting
31st May 20237:00 amRNSAnnual General Meeting
22nd May 20236:13 pmRNSDirector/PDMR Shareholding
28th Apr 20235:57 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.